| Year |
Citation |
Score |
| 2023 |
Otte A, Soh BK, Park K. The Impact of Post-Processing Temperature on PLGA Microparticle Properties. Pharmaceutical Research. PMID 37589826 DOI: 10.1007/s11095-023-03568-z |
0.398 |
|
| 2022 |
Garner J, Skidmore S, Hadar J, Park H, Park K, Otte A, Jhon YK, Xu X, Qin B, Wang Y. Scanning Analysis of Sequential Semisolvent Vapor Impact To Study Naltrexone Release from Poly(lactide-co-glycolide) Microparticles. Molecular Pharmaceutics. PMID 36166409 DOI: 10.1021/acs.molpharmaceut.2c00595 |
0.521 |
|
| 2022 |
Otte A, Turasan H, Park K. Implications of particle size on the respective solid-state properties of naltrexone in PLGA microparticles. International Journal of Pharmaceutics. 626: 122170. PMID 36070842 DOI: 10.1016/j.ijpharm.2022.122170 |
0.404 |
|
| 2022 |
Otte A, Park K. Transitioning from a lab-scale PLGA microparticle formulation to pilot-scale manufacturing. Journal of Controlled Release : Official Journal of the Controlled Release Society. 348: 841-848. PMID 35752252 DOI: 10.1016/j.jconrel.2022.06.036 |
0.479 |
|
| 2022 |
Park K, Otte A, Park H. Perspective on drug delivery in 2050. Journal of Controlled Release : Official Journal of the Controlled Release Society. 344: 157-159. PMID 35202744 DOI: 10.1016/j.jconrel.2022.02.025 |
0.493 |
|
| 2021 |
Park H, Otte A, Park K. Evolution of drug delivery systems: From 1950 to 2020 and beyond. Journal of Controlled Release : Official Journal of the Controlled Release Society. 342: 53-65. PMID 34971694 DOI: 10.1016/j.jconrel.2021.12.030 |
0.514 |
|
| 2021 |
Sharifi F, Otte A, Park K. Initial Formation of the Skin Layer of PLGA Microparticles. Advanced Healthcare Materials. e2101427. PMID 34601826 DOI: 10.1002/adhm.202101427 |
0.447 |
|
| 2021 |
Sharifi F, Meqbil YJ, Otte A, Gutridge AM, Blaine AT, van Rijn RM, Park K. Engineering Quick- and Long-acting Naloxone Delivery Systems for Treating Opioid Overdose. Pharmaceutical Research. PMID 34114163 DOI: 10.1007/s11095-021-03069-x |
0.412 |
|
| 2021 |
Otte A, Damen F, Goergen C, Park K. Coupling the in vivo performance to the in vitro characterization of PLGA microparticles. International Journal of Pharmaceutics. 120738. PMID 34048931 DOI: 10.1016/j.ijpharm.2021.120738 |
0.428 |
|
| 2020 |
Park K, Otte A, Sharifi F, Garner J, Skidmore S, Park H, Jhon YK, Qin B, Wang Y. Potential Roles of the Glass Transition Temperature o wf PLGA Microparticles in Drug Release Kinetics. Molecular Pharmaceutics. PMID 33331774 DOI: 10.1021/acs.molpharmaceut.0c01089 |
0.565 |
|
| 2020 |
Park K, Otte A, Sharifi F, Garner J, Skidmore S, Park H, Jhon YK, Qin B, Wang Y. Formulation composition, manufacturing process, and characterization of poly(lactide-co-glycolide) microparticles. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 33148404 DOI: 10.1016/j.jconrel.2020.10.044 |
0.556 |
|
| 2020 |
Otte A, Sharifi F, Park K. Interfacial tension effects on the properties of PLGA microparticles. Colloids and Surfaces. B, Biointerfaces. 196: 111300. PMID 32919245 DOI: 10.1016/J.Colsurfb.2020.111300 |
0.566 |
|
| 2020 |
Sharifi F, Otte A, Yoon G, Park K. Continuous in-line homogenization process for scale-up production of naltrexone-loaded PLGA microparticles. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 32645336 DOI: 10.1016/J.Jconrel.2020.06.023 |
0.585 |
|
| 2019 |
Park K, Skidmore S, Hadar J, Garner J, Park H, Otte A, Soh BK, Yoon G, Yu D, Yun Y, Lee BK, Jiang X, Wang Y. Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 31071374 DOI: 10.1016/J.Jconrel.2019.05.003 |
0.54 |
|
| 2019 |
Park K, Otte A. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities. Annual Review of Biomedical Engineering. PMID 30786212 DOI: 10.1146/Annurev-Bioeng-060418-052155 |
0.442 |
|
| 2018 |
Otte A, Soh BK, Yoon G, Park K. Liquid crystalline drug delivery vehicles for oral and IV/subcutaneous administration of poorly soluble (and soluble) drugs. International Journal of Pharmaceutics. PMID 29371020 DOI: 10.1016/J.Ijpharm.2018.01.037 |
0.563 |
|
| 2017 |
Otte A, Báez-Santos YM, Mun EA, Soh BK, Lee YN, Park K. The in vivo transformation and pharmacokinetic properties of a liquid crystalline drug delivery system. International Journal of Pharmaceutics. PMID 28844902 DOI: 10.1016/J.Ijpharm.2017.08.098 |
0.548 |
|
| 2016 |
Báez-Santos YM, Otte A, Mun EA, Soh BK, Song CG, Lee YN, Park K. Formulation and characterization of a liquid crystalline hexagonal mesophase region of phosphatidylcholine, sorbitan monooleate, and tocopherol acetate for sustained delivery of leuprolide acetate. International Journal of Pharmaceutics. 514: 314-321. PMID 27863678 DOI: 10.1016/J.Ijpharm.2016.06.138 |
0.596 |
|
| 2016 |
Baez-Santos YM, Otte A, Park K. A Fast and Sensitive Method for the Detection of Leuprolide Acetate: A High-Throughput Approach for the In Vitro Evaluation of Liquid Crystal Formulations. Analytical Chemistry. PMID 27040983 DOI: 10.1021/Acs.Analchem.6B00190 |
0.505 |
|
| 2014 |
Boksa K, Otte A, Pinal R. Matrix-assisted cocrystallization (MAC) simultaneous production and formulation of pharmaceutical cocrystals by hot-melt extrusion. Journal of Pharmaceutical Sciences. 103: 2904-10. PMID 24807421 DOI: 10.1002/Jps.23983 |
0.384 |
|
| 2012 |
Otte A, Zhang Y, Carvajal MT, Pinal R. Milling induces disorder in crystalline griseofulvin and order in its amorphous counterpart Crystengcomm. 14: 2560. DOI: 10.1039/C2Ce06365D |
0.339 |
|
| 2011 |
Otte A, Carvajal MT. Assessment of milling‐induced disorder of two pharmaceutical compounds Journal of Pharmaceutical Sciences. 100: 1793-1804. PMID 21374615 DOI: 10.1002/Jps.22415 |
0.313 |
|
| 2011 |
Yamauchi M, Lee EH, Otte A, Byrn SR, Carvajal MT. Contrasting the surface and bulk properties of anhydrate and dehydrated hydrate materials Crystal Growth and Design. 11: 692-698. DOI: 10.1021/Cg101098V |
0.309 |
|
| Show low-probability matches. |